Summit Therapeutics stock jumps as ivonescimab extends survival in China
Shares of Summit Therapeutics rose more than 12% Thursday morning after the company said ivonescimab is extending survival in a Chinese lung cancer study, lifting the stock to $16.46.
By Bill AlpertShares of the drug developer Summit Therapeutics were up more than 12% Thursday morning on news that its drug is performing well in a Chinese lung cancer study.Summit stock jumped to $16.46 after the Miami-based start-up said that its drug ivonescimab was extending the survival of lun…